Clinical trials: malaria, open to volunteers
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Malaria Transmission, Malaria Prevention
Long-acting Spatial Emanators / Repellents (LASER)
Malaria is a major problem in western Kenya, particularly around Lake Victoria. Whilst current prevention methods like bed nets and vaccines help to reduce malaria burden, additional tools are needed to better protect communities…
- Conditions
- Malaria Transmission, Malaria Prevention, Malaria
- Trial name
- LASER (NCT07387341)
- Testing
- Guardian, IRS with Pirimiphos - methyl
- Where
- Kenya
- Volunteers
- 22,815 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine
The ongoing Malaria Vaccine Pilot Evaluation (MVPE) is being conducted in Ghana, Malawi and Kenya through community and sentinel hospital surveillance systems and a series of household surveys (to measure vaccine coverage).
- Trial name
- MVPE-CC (NCT05041556)
- Testing
- Case-control study of clinical outcomes, Case-control study of mortality outcome
- Where
- 4 sites in Ghana, Kenya and 1 more
- Volunteers
- 9,280 people
- Sponsor
- Kintampo Health Research Centre, Ghana
Malaria Asymptomatic Parasitaemia, Malaria Falciparum
Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections.
- Conditions
- Malaria Asymptomatic Parasitaemia, Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- NCT07389057
- Testing
- DHAP, Single low dose PQ
- Where
- Ghana
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Plasmodium Vivax Infection, Malaria Vaccine
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3.
- Trial name
- MIST3 (NCT05380388)
- Testing
- Malaria Vaccine, HBV vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Falciparum
A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
- Trial name
- NCT07545681
- Testing
- GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
This is a single-centre, participant- and investigator-blind, randomised, placebo controlled, single ascending dose study to assess the safety, tolerability and PK of a single dose of IM depot injection(s) of LAI formulations of…
- Trial name
- NCT07011511
- Testing
- MMV055 Dose 1, MMV055 Dose 2, MMV055 Dose 3
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Severe Malaria, Thrombocytopenia
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
Open-label randomized controlled trial to test the effectiveness of whole blood transfusion for improving survival in children with severe malaria complicated by thrombocytopenia.
- Trial name
- PLATFORM (NCT05711485)
- Testing
- Whole blood transfusion
- Where
- 2 sites in United States, Zambia
- Volunteers
- 132 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Malaria
A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months
The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
- Trial name
- NCT07036159
- Testing
- RTS,S/AS01E vaccine
- Where
- 2 sites in Rwanda
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria Infection, Malaria Vaccines
Comparison of Two Strategies for Administering the R21-Matrix M Vaccine in a Context of Seasonal Malaria Transmission in Chad
This is a two-arm, cluster-randomised, phase IV trial conducted in Chad to assess the protective efficacy and impact in real-life conditions of a new strategy for administering the R21/MM malaria vaccine, synchronized within a…
- Trial name
- COSAV-R21 (NCT07038837)
- Testing
- "Synchronised" arm (intervention)
- Where
- Chad
- Volunteers
- 70,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Splenectomy
Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations
Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating cells and to trigger an innate and adaptive response…
- Trial name
- SPLEENVIVO (NCT06418256)
- Testing
- Spleen, blood and plasma collection
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Vivax Malaria, G6PD Deficiency
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of…
- Trial name
- NCT07468513
- Testing
- Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose).
- Where
- 4 sites in Brazil, Ethiopia and 1 more
- Volunteers
- 100 people
- Sponsor
- Menzies School of Health Research
Malaria Vaccine
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
This is a clinical trial in which healthy volunteers will receive one of three investigational malaria vaccines (LYB014, LYB017, and LYB027) administered in combination with the A02B adjuvant, or the A02B adjuvant alone as the…
- Trial name
- NCT07831226
- Testing
- LYB014 low dose, LYB014 high dose, LYB017 low dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Malaria
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Background: Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away.
- Trial name
- NCT02471378
- Where
- Mali
- Volunteers
- 7,476 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute